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ABSTRACT 
Objective: Development of new semi-synthetic route for Coenzyme Q10 from solanesol isolated from tobacco waste and structural characterization 
by FT-IR, 1H & [13]C NMR, LC-MS spectral data and elemental analyses.  
Methods: The authors described herein a new, short and highly efficient semi-synthetic route for Coenzyme Q10 (Scheme 1,2&3) starting with 
isolated solanesol (I) from tobacco waste via the formation of solanesol chloride (II), solanesol ester (III), solanesol acetone (IV) and isodecaprenol 
(V) as an intermediates. Later attachment of two subsections of the target, that is, a benzohydroquinone as an important precursor (VII), and an 
isodecaprenol (V, 50 carbon chain) was anticipated to occur via a zinc chloride catalyzed coupling reaction obtained Coenzyme Q10 (VI) in 90.00 % 
isolated yield. The synthesized compounds were characterized by FT-IR, 1H & [13]C NMR, LC-MS spectral data and elemental analyses. 
Results: Coenzyme Q10 has been semi-synthesized by a novel process from the solanesol isolated from tobacco waste (biological waste) using 
readily available and inexpensive precursors like PCl3, ethyl acetoacetate, Grignard reagent and benzohydroquinone derivative via the formation of 
important precursor Isodecaprenol and optimizing the each reaction. The overall yield of Coenzyme Q10 was 17.24% under the optimized 
conditions.  
Conclusion: This process achieved CoQ10 starting from an abundantly available solanesol from tobacco waste. Further improvement in the coupling 
reaction between Isodecaprenol (V) and Benzohydroquinone (VII) in the presence of Lewis acid may lead to a better and viable synthetic process. 
Hence this process may be economical and potential to be used for large-scale production. 
Keywords: Coenzyme Q10, Isodecaprenol, Solanesol, Coupling reaction. 
 
INTRODUCTION 
Coenzyme Q10 (CoQ10) is a renowned member of the ubiquinone 
family, a vitamin-like nutrient and an essential component of the 
mitochondrial electron transfer chain because it is present in every 
cell in the human body accounts for its another name: ubiquinone. It 
is required for ATP synthesis and functions as an antioxidant in cell 
membranes and lipoproteins [1]. It has three decades of recognition 
in biomedical science; the combination of a polar head group 
attached to a 50 carbon tail is a remarkable construct of fruition and 
frequently referred to as the “miracle nutrient”, [2] CoQ10 plays a 
role in maintaining human health and vigor.  
It is naturally synthesized in the body. The quinone ring of CoQ10 is 
synthesized from the aminoacids, tyrosine and phenylalanine and 
the polyprenyl side chain is synthesized from acetyl-CoA. A few of its 
many intrinsic worth are involvement in mitochondrial processes 
such as respiration, cellular production of ATP, maintenance of heart 
muscle strength, quenching of free radicals in the battle against 
aging, and enhancement of the immune system [3]. CoQ9 was found 
in rodents like mice and rats, while CoQ6, CoQ7 and CoQ8, were found 
in yeast and bacteria [4,5]. Literature review suggested that the 
CoQ10 exerts its antioxidant property by its reduced form (Figure 1) 


































Oxidized form of coenzyme Q
         (Q, ubiquinone)
Semiquinone intermediate
               (QH+)
Reduced form of coenzyme Q
          (QH2, ubiquinol)  
Fig. 1: Oxidized and Reduced forms of Coenzyme Q. 
 
Like CoQ10, CoQ9 is not simply a compound responsible for energy 
transduction in mitochondrial membrane in rat heart: it also serves 
as a functional element in the cells and possesses ability for redox 
cycling. The CoQ10 differs from CoQ9 with respect to the number of 
isoprenoid units in the tail; CoQ10 has ten units in contrast to the 
presence of nine units in CoQ9. The majority of the CoQ10 is found in 
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mammalian hearts including human myocardium [6] and is not an 
essential nutrient, because it can be synthesized in the body. And 
also found high amounts of CoQ10 in several food products including 
meat, fish, peanuts and broccoli [7].  
It is also used in the treatment of periodontal disease, diabetes, 
Parkinson’s, Alzheimer’s, Huntington’s disease and to help 
counteract the aging process. It is also effective in relieving certain 
brain disorders by temporarily restoring mitochondrial activity in 
cells. There are two major factors that lead to deficiency of CoQ10 in 
humans: reduced biosynthesis, and increased utilization by the 
body. It is not toxic (there are no reported side effects). It is 
generally employed as a supplement, rather than a replacement for 
standard medical treatment. Dietary intake of CoQ10 is about 2-5 
mg/day, which is inadequate for the body under pathophysiological 
conditions [8]. Although much of society is lack of awareness of the 
importance of ubiquinone, but chemists have devoted considerable 
effort in attempting to devise economically viable routes to this 
nutraceutical [9] as well as its lower homologues [10] since the first 
industrial approach by Hideki Fukawa at Nisshin in 1974 [11]. 
The authors describe herein a new, short and highly efficient semi-
synthetic process for Coenzyme Q10 (Scheme 1,2&3) using 
retrosynthetic analysis starting with isolated solanesol from tobacco 
waste [12]. Starting with solanesol (I) and isodecaprenol (V) could 
be prepared as illustrated in Scheme 2. Thus, conversion of (I) to the 
corresponding chloride (II) (94 %) is best done using phosphorous 
trichloride (PCl3) in dimethylformamide (DMF), which gives rise to 
material of excellent quality simply upon workup. Treatment of (II) 
with ethyl acetoacetate, phase transfer catalyst and potassium 
carbonate in tetrahydrofuran (THF) gives intermediate (III), in 85% 
isolated yield. Exposure of (III) to warm alcoholic potassium 
hydroxide solution (10%) yielded solanesol acetone (IV) which 
upon treating with vinyl magnesium bromide in THF led essentially 
quantitatively to isodecaprenol (V). Attachment of two subsections 
of the target, that is, a benzohydroquinone (an aromatic precursor, 
VII), and an isodecaprenol (V) lipophilic hydrocarbon side chain, 
was anticipated to occur via a zinc chloride catalyzed coupling 
reaction obtained CoQ10 in 90 % isolated yield (Scheme 3).  
MATERIALS AND METHODS 
Chemistry 
All reagents and solvents were used as purchased without further 
purification. Melting points were determined on a standard Boetius 
apparatus and are uncorrected. The IR spectra were recorded in 
Perkin-Elmer BXF1 FT-IR spectrophotometer using KBr disc 
method. 1H and [13]C NMR spectra were recorded in the indicated 
solvent on a Bruker AMX 400 and 100 MHz respectively with 
tetramethylsilane (TMS) as internal standard (chemical shifts in δ 
ppm). The splitting patterns of 1H-NMR were designed as follows: s: 
singlet, d: doublet, t: triplet, q: quartet, m: multiplet. The LC-MS 
[API/ESI-MS (80 eV)] spectra were recorded on Agilent HPLC 1100 
series. The elemental analyses of the synthesized compounds were 
recorded on Carlo Erba 1108 elemental analyzer and were within ± 
0.4% of the theoretical values. TLC was performed on Silica Gel F 254 
plates (Merck) with visualization by UV (254 nm) chamber with 
protective filters. The major chemicals ethyl acetoacetate, 
tetrabutylammonium bromide, vinyl magnesium bromide were 
purchased from Sigma-Aldrich Chemical Corporation, USA. All other 
chemicals were of analytical grade. All the synthesized compounds 
have been purified by suitable crystallization procedure.  
Experimental 
Synthesis of solanesol chloride (II) from solanesol (I) 
Phosphorus trichloride (1 ml, 0.01 mol) was added to a cooled 
dimethyl formamide (2 ml) at 10 °C slowly and the mixture was 
allowed to stand at room temperature for 90 minutes. To the 
mixture obtained was added a solution of solanesol, I (5.0 g, 0.007 
mol) in toluene (10 ml) slowly at 10 °C. After addition, the reaction 
mixture was stirred for 90 min, poured into cold water (50 ml) and 
extracted with ethyl acetate (2 x 20 ml). Ethyl acetate extract was 
dried over sodium sulphate and concentrated under vacuum to give 
solanesol chloride, II (3.40 g). 
1-Chloro-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-
2,6,10,14,18,22,26,30,34-nonaene (II): White solid, yield 78.0 %, mp 
40-42 °C. IR (KBr, cm-1): 2982 (CH), 2926 (CH), 1632 (C=C), 1446 
(CH2), 1372 (CH3), 846 (C–Cl). 1H NMR (CDCl3, δ ppm): 1.23-1.26 
(32H, m, 16 CH2), 1.59 (3H, s, CH3), 1.67 (3H, s, CH3), 1.72 (3H, s, 
CH3), 2.03 (21H, s, 7 CH3), 4.08-4.14 (9H, m, 9 HC=), 5.10-5.13 (2H, t, 
OCH2). [13]C NMR (CDCl3, δ ppm): 140.4, 136.8, 135.8, 127.5, 124.6, 
45.6, 38.2, 29.8, 27.0, 25.5 and 21.4. LC-MS [API/ESI-MS (80 eV)] 
(m/z %): 673 (M++ Na), 614 (M+ - 31), 512 (M+ - 138), 471 (M+ - 
179), 409 (M+ - 241). Anal. Calcd for C45H73Cl: C, 83.14; H, 11.24; Cl, 
5.46. Found: C, 83.38; H, 11.21; Cl, 5.45. 
Synthesis of solanesol ester (III) from solanesol chloride (II) 
To a stirred mixture of solanesol chloride, II (3.40 g, 0.005 mol), 
toluene (15 ml), tetra-n-butylammonium bromide (TBAB) as phase 
transfer catalyst (PTC) (1.70 g, 0.005 mol) and potassium carbonate 
(0.7 g, 0.005 mol), was added ethyl acetoacetate (0.65 g, 0.005 mol) 
and then the reaction mixture was stirred under reflux for 4 to 5 hr 
at room temperature. The reaction mass was cooled, washed with 
water (5 ml), dried over sodium sulfate and concentrated under 
vacuum to yield solanesol ester, III ( 3.0 g) as an oil.  
3-(3,7,11,15,19,23,27,31,35)-nonamethylhexatriaconta-
2,6,10,14,18,22,26,30,34-nonaene-ethyl acetoacetate (III): White 
solid, yield 80.0 %, mp 34-36 °C. IR (KBr, cm-1): 2957 (CH), 2923 
(CH), 2853 (CH), 1743 (C=O), 1698 (C=C), 1447 (CH2), 1372 (CH3), 
1236 [(C=O)-O]. 1H NMR (CDCl3, δ ppm): 0.78-0.89 (5H, m, CH2CH3), 
1.23-1.27 (32H, m, 16 CH2), 1.42 (3H, s, CH3), 1.67 (3H, s, CH3), 1.70 
(3H, s, CH3), 1.75 (3H, s, CH3), 2.04 (21H, s, 7 CH3), 2.21 (1H, s, CH), 
4.09-4.14 (9H, m, 9 HC=), 5.09-5.13 (2H, t, CH2). LC-MS [API/ESI-MS 
(80 eV)] (m/z %): 766 (M++ Na), 587 (M+ - 156), 171 (M+ - 572), 92 
(M+ - 651). Anal. Calcd for C51H82O3: C, 82.37; H, 11.04; O, 6.46. 
Found: C, 82.84; H, 11.04; O, 6.45.  
Synthesis of solanesol acetone (IV) from solanesol ester (III) 
A mixture of solanesol ester, III (3.0 g, 0.004 mol) in methanol (15 
ml), 10% methanolic potassium hydroxide solution (10 ml) were 
heated to reflux for 2 hr at 50-55 °C. Methanol was removed by 
distillation under vacuum, neutralized with acetic acid and extracted 
with ethyl acetate (2 x 20 ml). The combined extract was 
concentrated to give solanesol acetone, IV (2.0 g).  
3-(3,7,11,15,19,23,27,31,35)-nonamethylhexatriaconta-
2,6,10,14,18,22,26,30,34-nonaene-propan-2-one (IV): White solid, 
yield 70.0 %, mp 38-40 °C. IR (KBr, cm-1): 2957 (CH), 2918 (CH), 
2849 (CH), 1716 (C=O), 1683 (C=C), 1447 (CH2), 1379 (CH3), 1102 
[C-(C=O)-C]. 1H NMR (CDCl3, δ ppm): 1.24-1.27 (32H, m, 16 CH2), 
1.59 (3H, s, CH3), 1.67 (3H, s, CH3), 1.97 (3H, s, CH3), 1.99 (3H, s, 
CH3), 2.04 (21H, s, 7 CH3), 2.08 (2H, s, CH2), 4.09-4.14 (9H, m, 9 HC=), 
5.09-5.13 (2H, t, CH2). LC-MS [API/ESI-MS (80 eV)] (m/z %): 711 
(M++ K), 262 (M+ - 409), 171 (M+ - 500), 92 (M+ - 579). Anal. Calcd for 
C48H78O: C, 85.84; H, 11.62; O, 2.38. Found: C, 86.28; H, 11.64; O, 2.38.  
Synthesis of Isodecaprenol (V) from solanesol acetone (IV)  
To a cooled vinyl magnesium bromide (10 ml, 1 M solution) at 10 °C 
was added a solution of solanesol acetone, IV (2.0 g, 0.003 mol) in 
tetrahydrofuran (8 ml) over a period of 30 minutes and the reaction 
mixture was further stirred at room temperature for 2 to 3 hr. The 
reaction mass was cooled to 10°C and to this was added a solution of 
ammonium chloride (1.5 g) in water (40 ml). The pH of the reaction 
mass was adjusted to 7 with acetic acid, extracted with ethyl acetate 
(2 x 50 ml), dried over sodium sulfate and concentrated under 
vacuum to afford isodecaprenol, V (1.2 g) as whitish waxy solid.  
3-Hydroxy-3-methyl-4-(3,7,11,15,19,23,27,31,35)-
nonamethylhexatriaconta-2,6,10,14,18,22, 26,30,34-nonaene-butan-1-
ene (V): White solid, yield 72.50 %, mp 34-36 °C. IR (KBr, cm-1): 
3418 (OH), 2926 (CH), 2857 (CH), 1652 (C=C), 1444 (CH2), 1372 
(CH3). 1H NMR (CDCl3, δ ppm): 1.24-1.27 (32H, m, 16 CH2), 1.55 (3H, 
s, CH3), 1.59 (3H, s, CH3), 1.67 (3H, s, CH3), 1.95-1.99 (1H, t, HC=), 
2.04 (21H, s, 7 CH3), 2.06-2.08 (2H, d, J = 7.6 Hz, CH2), 2.13 (3H, s, 
CH3), 3.63 (2H, m, CH2), 4.09-4.14 (9H, m, 9 HC=), 5.09-5.13 (2H, t, 
CH2). LC-MS [API/ESI-MS (80 eV)] (m/z %): 722 (M++ Na), 668 (M+ - 
31), 533 (M+ - 166), 325 (M+ - 374), 262 (M+ - 437), 171 (M+ - 528). 
Atla et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 8, 499-502 
501 
Anal. Calcd for C50H82O: C, 85.84; H, 11.73; O, 2.28. Found: C, 86.18; 
H, 11.73; O, 2.28.  
Synthesis of Coenzyme Q10 (VI) from Isodecaprenol (V)  
To a mixture of 2,3-dimethoxy-5-methyl-1,4-benzohydroquinone, 
VII (0.182 g, 0.001 mol) and Isodecaprenol, V (1.2 g, 0.001 mol) in 
ether (5 ml) was added anhydrous zinc chloride (0.2 g, 0.001 mol) 
and catalytic amount of acetic acid and stirring continued until clear 
solution obtained. Then solvent was removed, residue was heated to 
45 °C for 40 minutes and dissolved in hexane (25 ml). Hexane 
solution was washed with 75% aqueous methanol, dried over 
sodium sulfate and solvent removed to give a residue, which was 
purified by crystallization using hexane-ethyl acetate (1:9) gave 
coenzyme Q10, VI (0.85 g). 
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-
decamethyltetra conta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-
dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione (VI): Orange 
yellow solid, yield 72.50 %, mp 34-36 °C. IR (KBr, cm-1): 2955 (CH), 
2924 (CH), 2853 (CH), 1646 (C=O), 1612 (C=C), 1263 (C-O-C), 1154 
(C-CO-C). 1H NMR (CDCl3, δ ppm): 1.53 (21H, s, 7 CH3), 1.57 (3H, s, 
CH3), 1.59 (3H, s, CH3), 1.67 (3H, s, CH3), 1.73 (3H, s, CH3), 1.95-1.99 
(18H, m, 9 CH2), 2.01 (3H, s, CH3), 2.04-2.09 (18H, m, 9 CH2), 3.17-
3.19 (2H, d, J = 7.2 Hz, CH2), 3.97 (3H, s, OCH3), 3.99 (3H, s, OCH3), 
5.04-5.12 (10H, t, 10 HC=). [13]C NMR (CDCl3, δ ppm): 185.64, 
144.56, 140.58, 139.76, 136.15, 135.64, 133.56, 125.05, 124.64, 
123.25, 116.62, 65.02, 47.02, 39.42, 36.40, 31.56, 29.00, 27.38, 
25.89, 22.64, 17.58 and 14.74. LC-MS [API/ESI-MS (80 eV)] (m/z %): 
886 (M++ Na), 752 (M+ - 111), 677 (M+ - 196), 481 (M+ - 382), 325 
(M+ - 538), 174 (M+ - 689). Anal. Calcd for C59H90O4: C, 82.04; H, 
10.43; O, 7.41. Found: C, 86.18; H, 11.73; O, 2.28.  
RESULTS and DISCUSSION 
Conversion of solanesol (I) to solanesol chloride (II) 
Chlorination of solanesol was tried with phosphorous trichloride/ 
thionyl chloride in solvents like benzene/toluene/dimethyl 
formamide. Reaction of solanesol with thionyl chloride in the ratio of 
1:0.7 was proceeding at a temperature of 50-55 °C but the quality of 
the product, obtained, was poor. The preparation of solanesol 
chloride was then tried with phosphorous trichloride in the mole 
ratio of 1:0.4 to 1 at a temperature of 25-40 °C. However, reaction of 
solanesol with phosphorous trichloride in a mole ratio of 1:0.5 gave 
good yield of solanesol chloride. Duration of 1.5 hr, a temperature of 
25-30 °C and dimethylformamide, as a solvent, were the more 
preferred conditions. 
Conversion of solanesol chloride (II) to solanesol ester (III) 
Reaction of solanesol chloride of formula II with ethyl acetoacetate 
to form solanesol ester of the formula III was carried out in the 
presence of bases like Na2CO3, K2CO3 or NaOEt using TBAB, TEBAC or 
CTAB as PTC. Solvents for the reaction used were toluene or ethyl 
acetate or 1,4-dioxane or dimethyl formamide at a temperature of 
70-110 °C. Reaction in the presence of base like sodium ethoxide 
was progressing well, but the quality of the product was not good. 
Then the reaction was tried using alkali metal carbonate in solvents 
like toluene, acetone, acetonitrile, dimethylformamide, N-methyl 
pyrrolidone, dimethyl sulfoxide etc. in the presence or absence of a PTC. 
The reaction was preferably conducted in toluene, acetone, acetonitrile 
etc. using alkali metal carbonate and TBAB as PTC. The temperature of 
90-100 °C and duration of 4-5 hr was ideal for the reaction.  
Conversion of solanesol ester (III) to solanesol acetone (IV) 
Hydrolysis of the solanesol ester was achieved in an alcohol like 
ethanol or methanol by using sodium hydroxide or potassium 
hydroxide. A temperature of 50-80 °C and duration of 2-4 hr was 
preferred. The reaction was more preferably carried out in 10-20% 
methanolic potassium hydroxide for 2 hr at a temperature 55-60 °C 
to give the solanesol acetone of formula IV. 
Conversion of solanesol acetone (IV) to isodecaprenol (V) 
Solanesol acetone in tetrahydrofuran was treated with vinyl 
magnesium bromide under nitrogen atmosphere at a temperature 5-
35 °C for 2-3 hr. A temperature of 30 °C and reaction duration of 2 
hr was ideal to give crude isodecaprenol of the formula V. This crude 
product was crystallized from acetone or acetonitrile to give 






Conversion of isodecaprenol (V) to coenzyme Q10 (VI) 
Condensation of isodecaprenol (V) with 2, 3-dimethoxy-5-methyl 1, 
4-benzonhydroquinone (VII) was conducted in the presence of 
Lewis acids like BF3 etherate, aluminium chloride or zinc chloride as 
described below. Reaction of isodecaprenol (V) with 
benzohydroquinone derivative (VII) in the presence of AlCl3 was 
proceeding but side reactions were more. Then this reaction was 
tried in the presence of boric acid, where rate of reaction was very 
slow and yield of the product was very poor. Condensation of 
isodecaprenol (V) with hydroquinone derivative (VII) was 
conducted in the presence of BF3 etherate in nitromethane and 
hexane in a ratio of 2:1. Molar ratio of reactants and Lewis acid was 
Atla et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 8, 499-502 
502 
1:1. Temperature of the reaction was 35-40 °C. Quality of the 
product thus obtained, was good but not to satisfactory level. Then, 
condensation reaction was conducted in the presence of zinc 
chloride as Lewis acid. Coupling reaction was conducted using 
equimolar mixture of hydroquinone derivative of formula VII, 
isodecaprenol (V) and 0.5-1.5 moles of zinc chloride in the presence of 
catalytic amounts of alkanoic acids like acetic acids, propanoic acids, 
pivalic acid, monochloro acetic acid, trichloro acetic acid and 
trifluroacetic acid at a temperature of 30-55 °C. At a temperature of 30-
40 °C the rate of reaction was very slow. However, the best yield of 
coenzyme Q10 formula VI was obtained, when the coupling reaction of 
equimolar mixture of hydroquinone VII, isodecaprenol V and zinc 
chloride was conducted in the presence of acetic acid or trichloroacetic 





Coenzyme Q10 is a potentially useful compound having wide number 
of health applications especially those related to cardiovascular 
diseases. Though the CoQ10 from biotechnology process can able to 
meet the current demand, no commercially viable synthetic process 
is available. In the present study, we have developed a simple and 
effective method for the synthesis of Coenzyme Q10 by a novel 
process from the solanesol isolated from tobacco waste (biological 
waste) using readily available and inexpensive precursors like PCl3, 
ethyl acetoacetate, Grignard reagent and hydroquinone derivative 
via the formation of important precursor Isodecaprenol. The key 
parameters of each reaction were also optimized and the overall 
yield of Coenzyme Q10, VI was 17.24% under the optimized 
conditions. Hence this process was found to be economical, and has 
the potential to be used for large-scale process also.  
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